World Journal of Virology - Baishideng Publishing Group

BPG is committed to discovery and dissemination of knowledge

Cited by in CrossRef

For:	Rochoń J, Kalinowski P, Szymanek-Majchrzak K, Grąt M. Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease. World J Gastroenterol 2024; 30(23): 2964-2980 [PMID: 38946874 DOI: 10.3748/wjg.v30.i23.2964]
URL:	https://www.wjgnet.com/2220-3249/full/v30/i23/2964.htm

(137) (163) (0) (0) (0) (10) (9715) (30)

Number	Citing Articles
1	Andrea M. Tou, Jennifer Panganiban. Metabolic Bariatric Surgery as a Disease-Modifying Therapy for Pediatric Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) Within an Evolving Therapeutic Framework. The Journal of Pediatrics 2026; 293 doi: 10.1016/j.jpeds.2026.115011
2	Boris Dinkov, Diana Pendicheva-Duhlenska. The Interplay Between GLP-1-Based Therapies, the Gut Microbiome, and MASLD/MASH in Type 2 Diabetes Mellitus: A Narrative Review. Biomedicines 2026; 14(4) doi: 10.3390/biomedicines14040806
3	Evangelia E. Tsakiridis, Gregory R. Steinberg. Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression. Diabetes, Obesity and Metabolism 2026; 28(S2) doi: 10.1111/dom.70624
4	Wissam Ghusn, Mira Sridharan, Rachel Fromer, Muhammet Ozdemir, Madeleine G. Haff, Eric J. Vargas. Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications. Biomedicines 2025; 13(10) doi: 10.3390/biomedicines13102437
5	Xingjian Guo, Liou Zhu, Xianpeng Zhou, Chenxi Liang, XiaoLin Zhang, Chen Wang, Biao Yan. The bile acid-FXR axis as a critical target and mediator of pesticide-induced toxicity: Mechanisms and implications for hazard assessment. Journal of Hazardous Materials Advances 2026; 23 doi: 10.1016/j.hazadv.2026.101370
6	Hui Sun, Le Yang, Ye Sun, Xinya Zhang, Xin Sun, Xueping Zhao, Hui Sun, Qimeng Zhang, Guangli Yan, Xijun Wang. Dysregulated bile acid metabolism as a novel player in gout progression: emerging therapeutic strategies. Frontiers in Endocrinology 2025; 16 doi: 10.3389/fendo.2025.1676017
7	Karolina Kornatowska, Szymon Kopciał, Mateusz Wiekiera, Adrianna Wiekiera, Paweł Budzik, Mateusz Tyniec, Kamal Morshed. The Evolution of MASLD Management: From Revised Nomenclature to Disease-Modifying Therapies. Gastroenterology Insights 2026; 17(2) doi: 10.3390/gastroent17020033
8	Chia‐Chih Kuo, Min‐Hsiang Chuang, Chun‐Hsien Li, Ya‐Wen Tsai, Po‐Yu Huang, Hsing‐Tao Kuo, Chih‐Cheng Lai. Glucagon‐Like Peptide‐1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes. Alimentary Pharmacology & Therapeutics 2025; 61(7) doi: 10.1111/apt.18502
9	Houda Zoubiri, Wassila Saiah, Amel Otmane, Hamza Saidi, Mohamed Makrelouf, Samir Ait Abderrhmane, Ali El Mahdi Haddam, Elhadj-Ahmed Koceir. Plasma GLP-1 (Glucagon-like Peptide-1) Depletion Is Correlated with Dysregulation of Adipocytokine in Type 2 Diabetic Patients With or Without Metabolic-Associated Fatty Liver Disease (MAFLD): A Cross-Sectional Study Related to Gender-Sex Disparities. International Journal of Molecular Sciences 2026; 27(3) doi: 10.3390/ijms27031218
10	Yu.M. Stepanov, O.V. Zinych, I.A. Klenina, K.O. Shyshkan-Shyshova, N.M. Kushnarоva. Efficacy of liraglutide in patients with metabolic-associated steatotic liver disease in type 2 diabetes mellitus. GASTROENTEROLOGY 2025; 59(2) doi: 10.22141/2308-2097.59.2.2025.675
11	Diego F. Wyszynski. Non-alcoholic Fatty Liver Disease in Pregnancy: Clinical Implications, Adverse Outcomes, and Therapeutic Considerations. Journal of Clinical and Experimental Hepatology 2026; 16(2) doi: 10.1016/j.jceh.2025.103431
12	Metin Basaranoglu, Merve Guney-Coskun. Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy. World Journal of Gastroenterology 2024; 30(43): 4682-4688 doi: 10.3748/wjg.v30.i43.4682 Abstract(576) \| Core Tip(571) \| Full Article(HTML)(7779) \| Full Article (PDF)-1223K(338) \| Full Article with Cover (PDF)-1577K(195) \| Full Article (XML)-96K(113) \| Audio-1593K(15) \| Peer-Review Report-245K(126) \| Answering Reviewers-147K(106) \| Times Cited (19) \| Total Visits (8914) \| Open
13	Andrzej S Tarnawski. Editor-in-Chief articles of choice and comments from January to June 2024. World Journal of Gastroenterology 2024; 30(34): 3875-3882 doi: 10.3748/wjg.v30.i34.3875 Abstract(830) \| Core Tip(847) \| Full Article(HTML)(1780) \| Full Article (PDF)-410K(157) \| Full Article with Cover (PDF)-639K(214) \| Full Article (XML)-117K(133) \| Audio-785K(15) \| Peer-Review Report-230K(126) \| Answering Reviewers-209K(132) \| Times Cited (0) \| Total Visits (2284) \| Open
14	Irshad Khan, Sarasa Meenakshi, Md. Abubakar, Nitesh Kumar, Vinod L Gaikwad, Amita Rai, Krishna Murti. Tirzepatide as a multi-organ integrator in metabolic diseases: a review of molecular mechanisms and clinical translation. Endocrine 2026; 91(1) doi: 10.1007/s12020-026-04686-5
15	Tzu-Hurng Cheng, Wen-Rui Hao, Chun-Han Cheng. Role of intestinal glucagon-like peptide-1 in hypoglycemia response impairment in type 1 diabetes. World Journal of Diabetes 2024; 15(11): 2237-2241 doi: 10.4239/wjd.v15.i11.2237 Abstract(529) \| Core Tip(562) \| Full Article(HTML)(3999) \| Full Article (PDF)-365K(140) \| Full Article with Cover (PDF)-801K(141) \| Full Article (XML)-41K(113) \| Audio-213K(13) \| Peer-Review Report-237K(123) \| Answering Reviewers-97K(120) \| Times Cited (0) \| Total Visits (4393) \| Open
16	Ioannis Ilias, Lina Zabuliene, Manfredi Rizzo. GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks. Frontiers in Clinical Diabetes and Healthcare 2025; 5 doi: 10.3389/fcdhc.2024.1530811
17	Bisma Fatima Hammad, Nimrah Zafar, Muneeb Ullah, Syeda Jazilah Faisal, Fizzah Iftikhar, Haadia Waheed, Muhammad Waleed Muzaffar, Khadija Ahmed, Faz Ashraf, Komal Zahid, Maimoona Akhtar, Mohammed Mahmmoud Fadelallah Eljack. Exploring the multifaceted roles of GLP-1 receptor agonists; a comprehensive review. Frontiers in Clinical Diabetes and Healthcare 2025; 6 doi: 10.3389/fcdhc.2025.1590530
18	Yining Xu, Daniel J Drucker, Giovanni Traverso, Ana Beloqui. Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies. Endocrine Reviews 2026; 47(1) doi: 10.1210/endrev/bnaf027
19	Jerome Lian, Mohan Patil, Ricky R. Lareu, Marco Falasca. Acute Effects of Cannabinoid Combination Therapies in a Western Diet-Induced Murine Model of Metabolic Liver Disease. International Journal of Molecular Sciences 2026; 27(11) doi: 10.3390/ijms27114872
20	Guangkui Bu, Yu Li, Guangfu Lin, Lichun Han, Deyi Chen, Xiaoping Lv. Agmatine protects against MAFLD via decreasing RBM15/IGF2BP2-mediated m6A modification of SREBP1. Molecular Biology Reports 2026; 53(1) doi: 10.1007/s11033-026-11909-5
21	Nian Liu, Ruiqi Wang, Yanyan Gao, Huaxin Wei, Fangying Xu, Shu Chen, Zhiling Yu, Lin Chen, Xiaohui Fan, Jiannan Qiu, Xiaobing Dou. Biochanin A alleviates HFD-Induced MAFLD by inhibiting IRE1α-SPT-ceramide axis and improving intestinal homeostasis. Phytomedicine 2026; doi: 10.1016/j.phymed.2026.158558
22	Yonglu Li, Xin Gao, Lihan Jiang, Hongdi Song, Chen Yang, Cong Wu, Yapeng Li, Shihai Yan, Ping Li, Qing Gu. Beyond the oral niche: Lacticaseibacillus paracasei LPC-37 unlocks oral-gastric-intestinal crosstalk for butyric acid-dependent oral inflammation alleviation. Food & Function 2025; 16(20) doi: 10.1039/D5FO02279G
23	Mykhailo Buchynskyi, Iryna Kamyshna, Iryna Halabitska, Pavlo Petakh, Oksana Kunduzova, Valentyn Oksenych, Oleksandr Kamyshnyi. Unlocking the gut-liver axis: microbial contributions to the pathogenesis of metabolic-associated fatty liver disease. Frontiers in Microbiology 2025; 16 doi: 10.3389/fmicb.2025.1577724
24	Li Lin, Shaowei Xiang, Yuan Chen, Yan Liu, Dingwen Shen, Xiaoping Yu, Zhe Wu, Yanling Sun, Kequan Chen, Jia Luo, Guilai Wei, Zhiguo Wang, Zhifeng Ning. Gut microbiota: Implications in pathogenesis and therapy to cardiovascular disease (Review). Experimental and Therapeutic Medicine 2024; 28(5) doi: 10.3892/etm.2024.12716
25	Yanqiu Li, Bingbing Zhu, Ke Shi, Yu Lu, Xuanwei Zeng, Yongqi Li, Qun Zhang, Ying Feng, Xianbo Wang. Advances in intrahepatic and extrahepatic vascular dysregulations in cirrhotic portal hypertension. Frontiers in Medicine 2025; 12 doi: 10.3389/fmed.2025.1515400
26	Chuwen Lin, Weijiong Chen, Shuang Liu, Baige Cao, Yan Ge, Yan Li, Yuanyuan Liu, Tiantian Guo, Jinfang Xu, Congrong Wang. Hongkou Advanced Research on Metabolism and Obesity iNtervention studY (HARMONY): a protocol for a longitudinal cohort study. BMJ Open 2026; 16(4) doi: 10.1136/bmjopen-2025-115236
27	Hui Wu, Zi-Heng Zhang, Ting Ye, Jia-Ni Chen, Tao-Hsin Tung, Jian-Sheng Zhu. Efficacy and safety of GLP-1 receptor agonists in patients with metabolic-associated fatty liver diseases: an umbrella review. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1783429
28	Andrea M. Tou, Jennifer Panganiban. Glucagon‐like peptide‐1 receptor agonists in pediatric metabolic dysfunction‐associated steatotic liver disease. Journal of Pediatric Gastroenterology and Nutrition 2026; 82(1) doi: 10.1002/jpn3.70242
29	Mona Mohamed Ibrahim Abdalla. Gut-liver axis in diabetes: Mechanisms and therapeutic opportunities. World Journal of Gastroenterology 2025; 31(29): 109090 doi: 10.3748/wjg.v31.i29.109090 Abstract(215) \| Core Tip(217) \| Full Article(HTML)(3501) \| Full Article (PDF)-4795K(173) \| Full Article with Cover (PDF)-6241K(149) \| Full Article (XML)-364K(69) \| Audio-364K(13) \| Peer-Review Report-260K(59) \| Answering Reviewers-194K(64) \| Times Cited (14) \| Total Visits (4394) \| Open
30	Xuejia Wang, Guangzhen Lu, Yingxue Zhou, Gang Zhao. GLP-1 receptor agonists in metabolic dysfunction–associated steatotic liver disease: mechanistic networks and translational implications: a review. Journal of Endocrinological Investigation 2026; doi: 10.1007/s40618-026-02891-7
31	Shereen A. El Sobky, Nada El-Ekiaby, Injie O. Fawzy, Amira Khaled Abdelhamid, Heba Attia, Ibrahim H. Fayed, Yasser Badr, Mohammed Emadeldeen, Ahmed Nagy, Mohamed Negm, Mohamed Sherif Negm, Ahmed Moustafa, Mohamed El-Kassas, Mohamed A. Farag, Ramy K. Aziz, Ahmed I. Abdelaziz. Association between the subcellular localization of host proteins and gut microbiome and metabolome in metabolic dysfunction-associated steatotic liver disease: a pilot study. Frontiers in Molecular Biosciences 2026; 13 doi: 10.3389/fmolb.2026.1703547
32	Junling Li, Qianru Gao, Hongtao Liu, Songlin Liu, Yanchun Wang, Xiongjie Sun, Junping Zheng, Huabing Yang, Baifei Hu. Integrating 16S rDNA sequencing analysis and targeted metabolomics to explore the mechanism of Xiexin Tang in treating atherosclerosis mice induced by high-fat diet. Journal of Pharmaceutical and Biomedical Analysis 2025; 259 doi: 10.1016/j.jpba.2025.116760
33	Zixuan Hu, Dianzhe Tian, Zuyi Yang, Junwei Zhang, Lei Zhang, Yiyao Xu, Xin Lu. The mechanisms of GLP-1 receptor agonists in liver diseases: their multifaceted impact on immune response and metabolic regulation. Frontiers in Pharmacology 2026; 17 doi: 10.3389/fphar.2026.1754721
34	Gui-Gui Yang, Yue-Hong Zhang, Qian-You Jia, He Zhang, Xin-Qin Li, Xue-Dong An. Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus. World Journal of Diabetes 2025; 16(11): 111280 doi: 10.4239/wjd.v16.i11.111280 Abstract(80) \| Core Tip(90) \| Full Article(HTML)(444) \| Full Article (PDF)-7411K(110) \| Full Article with Cover (PDF)-7610K(38) \| Full Article (XML)-175K(35) \| Audio-1045K(14) \| Peer-Review Report-277K(29) \| Answering Reviewers-142K(30) \| Supplementary Material-370K(38) \| Times Cited (1) \| Total Visits (736) \| Open